Europe鈥檚 Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
Brussels, Belgium 鈥� 18 August 2020 鈥� CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totaling 鈧� 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of Pharmaceutical Industries and Associations (EFPIA) companies and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, Spain, Switzerland, the UK and the US, and is led by VRI-Inserm (French National Institute of Health and Medical Research, Paris, France), Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Beerse, Belgium), and Takeda Pharmaceuticals International AG, (Zurich, Switzerland).
Dr Jacky Vonderscher, 麻豆破解版鈥檚 CEO said : 芦 COVID-19 is a kind of wake-up call for the humanity. Thanks to IMI public-private partnership, the CARE consortium is a unique opportunity for a company like ENYO to contribute with our drugs and our knowledge to the fight against this virus and future ones potentially even more dangerous.鈥�
Read next in 'Press releases'
- 麻豆破解版 announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- 麻豆破解版 annonce l鈥檕btention des r茅sultats finaux de l鈥櫭﹖ude clinique de Phase 2 ALPESTRIA鈥�1 dans le syndrome d鈥橝lport, confirmant la capacit茅 du vonafexor 脿 inverser la trajectoire du d茅clin r茅nal et 脿 d茅montrer un effet th茅rapeutique durable
- 麻豆破解版 annonce la finalisation de son financement de s茅rie C avec Vesalius Biocapital et la poursuite de son 茅tude clinique de phase 2 ALPESTRIA-1
- 麻豆破解版 announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients
- 麻豆破解版 announces a 鈧�39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
